JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 163 filers reported holding JUNO THERAPEUTICS INC in Q4 2015. The put-call ratio across all filers is 2.35 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $10,297,000 | +815.3% | 225,251 | +798.4% | 0.01% | +600.0% |
| Q3 2017 | $1,125,000 | +65.2% | 25,073 | +10.1% | 0.00% | 0.0% |
| Q2 2017 | $681,000 | +18.6% | 22,779 | -11.9% | 0.00% | – |
| Q1 2017 | $574,000 | +277.6% | 25,858 | +220.6% | 0.00% | – |
| Q4 2016 | $152,000 | -29.6% | 8,066 | +12.0% | 0.00% | – |
| Q3 2016 | $216,000 | +2.9% | 7,203 | +31.7% | 0.00% | – |
| Q2 2016 | $210,000 | +6.6% | 5,470 | +5.9% | 0.00% | – |
| Q1 2016 | $197,000 | +12.6% | 5,164 | +30.0% | 0.00% | – |
| Q4 2015 | $175,000 | +26.8% | 3,972 | +17.5% | 0.00% | – |
| Q3 2015 | $138,000 | – | 3,380 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |